Inclusion Criteria:

          -  Histologically confirmed CD20 positive mantle cell lymphoma;

          -  Patients with MCL-related symptomatic and need immediate therapy; Include any of the
             following: (1) Blastoid variant (2) Pleomorphic variant (3) Ki-67 ≥30% (4) Bulky mass
             > 7 cm or ≥2 tumors, each ≥5 cm in diameter (5) Mutations in TP53, c-MYC or NOTCH
             genes (6) Size of spleen ≥20 cm (7) Lymphoma B symptoms (8) Mantle Cell International
             Prognostic Score (MIPI) > 3 (9) Lymphoma threatening organ function (10) Elevated
             lactate dehydrogenase (11) Peripheral blood white blood cell > 50×10^9/L (12)
             Pancytopenia due to bone marrow involvement (13) Pain due to lymphoma;

          -  Patients received no prior anti-lymphoma treatment;

          -  At least one evaluable lesion according to 2014 Lugano criteria;

          -  Ann Arbor stage II-IV;

          -  Eastern Cooperative Oncology Group (ECOG) of 0-2;

          -  Life expectancy > 3 months;

          -  Able to participate in all required study procedures;

          -  Proper functioning of the major organs: 1) The absolute value of neutrophils
             (>1.5×10^9/L); 2) platelet count (> 75×10^9/L); 3) Hemoglobin (> 80 g/L); 4) Serum
             creatinine <1.5 times Upper Limit Normal (ULN) ; 5) Serum total bilirubin < 1.5 times
             ULN; 6) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 2.5 times
             ULN; 7) Coagulation function: International Normalized Ratio (INR), Prothrombin Time
             (PT), Activated Partial Thromboplastin Time (APTT) < 1.5 times ULN (unless the subject
             is receiving anticoagulant therapy and PT and APTT are within the expected range at
             screening time);

        Exclusion Criteria:

          -  Involvement of central nervous system (CNS)

          -  Patients with Hemophagocytic syndrome;

          -  Patients with active bleeding, bleeding tendency or require anticoagulation treatment;

          -  Patients require treatment with strong CYP3A inhibitors;

          -  Uncontrolled active infection, with the exception of tumor-related B symptom fever;

          -  History of human immunodeficiency virus (HIV) infection and/or patients with acquired
             immunodeficiency syndrome are known;

          -  Patients with active hepatitis B or active hepatitis C. Patients who are positive for
             hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening
             stage must pass further detection of hepatitis B Virus (HBV) DNA (no more than 1000
             IU/mL) and HCV RNA (no more than the lower limit of the detection method) in the row.
             Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 1000
             IU/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the
             group;

          -  Diagnosed with or receiving treatment for malignancy other than lymphoma;

          -  Pregnant or breastfeeding women;

          -  Other researchers consider it unsuitable for patients to participate in this study.